| Early childhood development coming of age: science through the life course MM Black, SP Walker, LCH Fernald, CT Andersen, AM DiGirolamo, C Lu, ... The Lancet 389 (10064), 77-90, 2017 | 3105 | 2017 |
| Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results from a large … DYC Heng, W Xie, MM Regan, MA Warren, AR Golshayan, C Sahi, ... Journal of clinical oncology 27 (34), 5794-5799, 2009 | 2369 | 2009 |
| Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial AV Balar, MD Galsky, JE Rosenberg, T Powles, DP Petrylak, J Bellmunt, ... The Lancet 389 (10064), 67-76, 2017 | 2218 | 2017 |
| Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer M Annala, G Vandekerkhove, D Khalaf, S Taavitsainen, K Beja, ... Cancer discovery 8 (4), 444-457, 2018 | 496 | 2018 |
| Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma … T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ... The Lancet Oncology 21 (12), 1574-1588, 2020 | 447 | 2020 |
| Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2 … DJ Khalaf, M Annala, S Taavitsainen, DL Finch, C Oja, J Vergidis, ... The Lancet Oncology 20 (12), 1730-1739, 2019 | 326 | 2019 |
| Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer KN Chi, SJ Hotte, EY Yu, D Tu, BJ Eigl, I Tannock, F Saad, S North, ... Journal of clinical oncology 28 (27), 4247-4254, 2010 | 291 | 2010 |
| Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients AA Azad, BJ Eigl, RN Murray, C Kollmannsberger, KN Chi European urology 67 (1), 23-29, 2015 | 197 | 2015 |
| Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors A Jimeno, GJ Weiss, WH Miller Jr, S Gettinger, BJC Eigl, ALS Chang, ... Clinical cancer research 19 (10), 2766-2774, 2013 | 194 | 2013 |
| A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel KN Chi, T Kheoh, CJ Ryan, A Molina, J Bellmunt, NJ Vogelzang, ... Annals of Oncology 27 (3), 454-460, 2016 | 163 | 2016 |
| Circulating tumor DNA reveals clinically actionable somatic genome of metastatic bladder cancer G Vandekerkhove, T Todenhöfer, M Annala, WJ Struss, A Wong, K Beja, ... Clinical cancer research 23 (21), 6487-6497, 2017 | 162 | 2017 |
| AR-V7 transcripts in whole blood RNA of patients with metastatic castration resistant prostate cancer correlate with response to abiraterone acetate T Todenhöfer, A Azad, C Stewart, J Gao, BJ Eigl, ME Gleave, AM Joshua, ... The Journal of urology 197 (1), 135-142, 2017 | 127 | 2017 |
| Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis A Karsan, BJ Eigl, S Flibotte, K Gelmon, P Switzer, P Hassell, D Harrison, ... Clinical chemistry 51 (8), 1525-1528, 2005 | 125 | 2005 |
| Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer G Vandekerkhove, JM Lavoie, M Annala, AJ Murtha, N Sundahl, S Walz, ... Nature Communications 12 (1), 184, 2021 | 121 | 2021 |
| Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer AI So, RJ Levitt, B Eigl, L Fazli, M Muramaki, S Leung, MCU Cheang, ... Clinical Cancer Research 14 (21), 6944-6954, 2008 | 101 | 2008 |
| Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer BJC Eigl, SE Eggener, J Baybik, S Ettinger, KN Chi, C Nelson, Z Wang, ... Clinical cancer research 11 (13), 4905-4911, 2005 | 82 | 2005 |
| Health-related quality of life for abiraterone plus prednisone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: results from a phase II … DJ Khalaf, K Sunderland, BJ Eigl, CK Kollmannsberger, N Ivanov, ... European urology 75 (6), 940-947, 2019 | 81 | 2019 |
| Targeting the apoptosis pathway in prostate cancer RR Zielinski, BJ Eigl, KN Chi The Cancer Journal 19 (1), 79-89, 2013 | 80 | 2013 |
| Palliative radiotherapy improves pain and reduces functional interference in patients with painful bone metastases: a quality assurance study JSY Wu, G Monk, T Clark, J Robinson, BJC Eigl, N Hagen Clinical oncology 18 (7), 539-544, 2006 | 75 | 2006 |
| A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195 BJ Eigl, S North, E Winquist, D Finch, L Wood, SS Sridhar, J Powers, ... Investigational new drugs 33, 969-976, 2015 | 63 | 2015 |
